Related Experiment Video
Updated: Apr 26, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Coagulation state in patients with Crohn's disease: the effect of infliximab therapy
Xiaobing Wang1, Ge Wang, Jinghui Wang
1aDepartment of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University bThe Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, People's Republic of China.
Insights
Infliximab (IFX) therapy improves hypercoagulable states in Crohn's disease (CD) patients by normalizing coagulation biomarkers. This study highlights IFX's role in managing CD-related coagulation abnormalities.
Area of Science:
- Gastroenterology
- Hematology
- Pharmacology
Background:
- Coagulation abnormalities are implicated in inflammatory bowel disease pathogenesis.
- The effect of infliximab (IFX) on coagulation in Crohn's disease (CD) remains understudied.
Purpose of the Study:
- Compare coagulation biomarkers between CD patients and controls.
- Evaluate IFX therapy's impact on coagulation status in CD patients.
Main Methods:
- Retrospective case-control and self-control study design.
- Analysis of laboratory tests including coagulation parameters, D-dimer, CRP, and ESR.
- Inclusion and exclusion criteria applied to medical records of CD patients and controls.
Main Results:
- Significant differences in most coagulation parameters between CD patients and controls.
- Normalization of coagulation parameters during IFX therapy.
- IFX significantly decreased fibrinogen and D-dimer levels in CD patients.
Conclusions:
- Infliximab therapy effectively ameliorates the hypercoagulable state in Crohn's disease patients.
- IFX treatment contributes to normalizing coagulation abnormalities associated with CD.
Background:
Growing evidence has shown that coagulation processes play an important role in disease pathogenesis and/or disease progression in patients with inflammatory bowel disease. However, no study has ever focused on the possible influence of infliximab (IFX) therapy on the coagulation status in patients with Crohn's disease (CD).
Objective:
To investigate the difference in the coagulation biomarkers between the CD patients and the control participants, and evaluate the impact of IFX usage on the coagulation status of CD patients.
Patients And Methods:
A retrospective study that included a case-control study and a self-control study was designed. The medical records of CD patients and control participants were evaluated according to the inclusion and exclusion criteria. The results of laboratory tests including blood routine, coagulation, D-dimer, C-reactive protein, and erythrocyte sedimentation rate were retrieved to assess the coagulation state.
Results:
In the case-control study, almost all the parameters showed a statistically significant difference between the CD patients and the control participants, except for activated partial thromboplastin time and thrombin time (the P value ranged from 0.000 to 0.002). Most of the values of the parameters reverted to normal over time during IFX therapy in the self-control study. Moreover, the fibrinogen concentration decreased obviously after IFX infusion (P=0.000) and the D-dimer concentration also decreased obviously by about half of the start value after IFX usage (P=0.018).
Conclusion:
IFX therapy could ameliorate the hypercoagulable state in patients with CD.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
05:08A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
Published on: March 1, 2022
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids